Please enable Javascript to use all features and improve your user experience.
EHC 2023
Programme
Search
EN
All people
Jessica Ailani
Sort by Type
Date
Invited speaker
Invited lecture
Acute Treatment
Further involvements
ePoster
P177
Efficacy of ubrogepant for the treatment of migraine symptoms during the prodrome (premonitory phase): results from the PRODROME trial
ePoster
P022
Atogepant demonstrates early functional and quality of life improvements for the preventive treatment of episodic migraine after prior inadequate response to treatment: results from the ELEVATE trial
ePoster
P112
Design of the ContemporAry ProspecTive Understanding of migraine Real-world Evidence (CAPTURE) study
ePoster
P096
Atogepant provides early improvements in daily functioning and quality of life: results from the PROGRESS chronic migraine trial
ePoster
P029
Benefit-Risk assessment based on number needed to treat and number needed to harm: Atogepant vs. calcitonin gene–related peptide monoclonal antibodies
ePoster
P117
Network meta-analysis comparing atogepant vs. CGRP mAbs on headache impact test-6 total scores in episodic and chronic migraine
ePoster
P049
Evaluation of rimegepant utilization patterns for acute and preventive treatment of migraine in a commercially insured population
ePoster
P051
Atogepant vs. rimegepant cost per treatment responder analysis for the preventive treatment of episodic migraine
ePoster
P106
Network meta-analysis of atogepant vs. CGRP mAbs on migraine-specific quality of life questionnaire v2.1 in episodic and chronic migraine
v1.22.0
© Conventus Congressmanagement & Marketing GmbH
Imprint
Privacy